Moleculin Biotech Inc represents a set of values and corporate philosophy that center around innovation and improving the lives of patients. They are dedicated to developing novel oncology drugs that target highly-resistant tumors. With a focus on cutting-edge technologies and research, Moleculin Biotech Inc aims to provide effective and accessible treatments for cancer patients worldwide. By prioritizing collaboration and transparency, the company fosters a culture of excellence and integrity. Moleculin Biotech Inc's commitment to scientific advancement and patient well-being drives their mission to revolutionize cancer therapies and make a lasting impact in the field of biotechnology.

Moleculin Biotech Inc is primarily present in the United States.

Moleculin Biotech Inc has accomplished several significant milestones. The company successfully completed its initial public offering (IPO) in 2016, marking a key achievement in its history. Moleculin Biotech Inc has also made notable advancements in the clinical development of its pipeline of oncology drugs, including Annamycin, which has shown promise in treating relapsed or refractory acute myeloid leukemia (AML). Furthermore, the company has received Orphan Drug Designation from the U.S. FDA for Annamycin, highlighting the potential for addressing unmet medical needs. Moleculin Biotech Inc continues to make strides in the field of biotechnology, aiming to bring innovative therapies to patients in need.

Moleculin Biotech Inc is a pharmaceutical company focused on developing anti-cancer drugs. Established in 2015, the Houston-based company aims to discover novel treatments for highly resistant tumors and viruses. Moleculin Biotech concentrates on developing small molecule drugs based on licensed technologies, such as Annamycin for the treatment of acute myeloid leukemia. The company's approach involves leveraging new compounds that have shown potential for significant anti-tumor activity. With a commitment to innovation and improving patient outcomes, Moleculin Biotech Inc continues to pave the way in the development of groundbreaking therapies for diverse cancers and viral diseases.

Some of the main competitors of Moleculin Biotech Inc in the market include pharmaceutical companies like Pfizer, Merck & Co., Novartis, and Bristol-Myers Squibb. These companies also focus on developing innovative treatment options and therapeutics in the biotechnology sector. Moleculin Biotech Inc competes with these companies by leveraging its unique research and development capabilities, and a diverse portfolio of potential drug candidates.

Moleculin Biotech Inc primarily operates in the pharmaceutical and biotechnology industry.

The business model of Moleculin Biotech Inc revolves around developing and commercializing innovative pharmaceuticals for the treatment of various types of cancers. The company aims to address unmet medical needs by focusing on developing targeted therapies and immunotherapies that can potentially provide improved outcomes for cancer patients. Moleculin Biotech Inc emphasizes research and development activities to advance its pipeline of novel drugs, with a particular focus on inhibitors of glycolysis, a key process in cancer cell metabolism. By leveraging its scientific expertise and strategic collaborations, Moleculin Biotech Inc strives to bring innovative cancer treatments to market and contribute to improving patient outcomes in the field of oncology.

Moleculin Biotech KGV ir -0,23.

Moleculin Biotech KUV ir 0.

AlleAktien kvalitātes vērtējums Moleculin Biotech ir 2/10.

Pašreiz nevar aprēķināt apgrozījumu Moleculin Biotech.

gaidāmā Moleculin Biotech peļņa ir -19,20 milj. USD.

Moleculin Biotech Inc. is a biopharmaceutical company focused on the development of therapies for cancer and other serious diseases. The company's business activities are divided into research and development of new products, as well as manufacturing and marketing of these products. They have a strong focus on collaboration and partnerships with international pharmaceutical companies for global distribution. Their flagship product WP1066, which targets tumor stem cells, has shown promising results in early clinical studies. They also have other promising candidates in their pipeline, such as Annamycin for the treatment of Acute Myeloid Leukemia (AML) and WP1122 for the treatment of gliomas. Overall, Moleculin Biotech strives to develop innovative therapies and effectively market their products globally.

Moleculin Biotech izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Moleculin Biotech vai uzņēmums nedod dividendes.

Moleculin Biotech ISIN ir US60855D2009.

Moleculin Biotech WKN ir A2QQM0.

Moleculin Biotech simbols ir MBRX.

Pēdējo 12 mēnešu laikā Moleculin Biotech maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Moleculin Biotech plāno maksāt dividendes 0 USD apmērā.

Moleculin Biotech pašreizējā dividendu rentabilitāte ir .

Moleculin Biotech maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos .

Moleculin Biotech pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Moleculin Biotech tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Moleculin Biotech apmērā 0 USD, kas tika izmaksāta 7.08.2024., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 7.08.2024..

Pēdējās dividendes izmaksa notika 7.08.2024..

Gadā 2023, Moleculin Biotech izmaksāja 0 USD dividendes.

Moleculin Biotech dividendes tiek izmaksātas USD.